Last reviewed · How we verify
Invirase
At a glance
| Generic name | Invirase |
|---|---|
| Sponsor | Saint Michael's Medical Center |
| Target | Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Gastritis
- Dyspepsia
- Flatulence
- Constipation
- Hepatitis
- Hyperglycemia
- Hypertriglyceridemia
- Fatigue
Serious adverse events
- Hepatocellular toxicity
- Increased hepatic transaminases (>20-fold ULN)
- Pancreatitis
- Esophagitis
- Portal hypertension
- Hepatosplenomegaly
- Intestinal obstruction
- Syncope
- Thrombophlebitis
- Wasting syndrome
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (PHASE2)
- Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Invirase CI brief — competitive landscape report
- Invirase updates RSS · CI watch RSS
- Saint Michael's Medical Center portfolio CI